Astellas Pharma Inc 2020 AR2
The report highlights Astellas Pharma Inc.'s progress during the fiscal year ended March 31, 2020, marking the second year of its Corporate Strategic Plan 2018. The company successfully offset the negative impact of patent expirations for core products through increased market penetration of XTANDI and strong initial sales of EVENITY. Astellas expanded its research and development capabilities by acquiring Audentes Therapeutics, Inc., establishing genetic regulation as its fifth Primary Focus area. Additionally, the company advanced its sustainability commitments by aligning with the UN Sustainable Development Goals, particularly Goal 3, and switching to renewable energy at key Japanese research centers to eliminate greenhouse gas emissions from those facilities.
Company: Astellas Pharma Inc
Sector: Manufacturing
Country: Japan
Year: 2020
Type: AR2
Pages: 146
Back to company
Astellas Pharma Inc
Annual Report
The report highlights Astellas Pharma Inc.'s progress during the fiscal year ended March 31, 2020, marking the second year of its Corporate Strategic Plan 2018. The company successfully offset the negative impact of patent expirations for core products through increased market penetration of XTANDI and strong initial sales of EVENITY. Astellas expanded its research and development capabilities by acquiring Audentes Therapeutics, Inc., establishing genetic regulation as its fifth Primary Focus area. Additionally, the company advanced its sustainability commitments by aligning with the UN Sustainable Development Goals, particularly Goal 3, and switching to renewable energy at key Japanese research centers to eliminate greenhouse gas emissions from those facilities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Published
Oct 9, 2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Employees